Cullinan Therapeutics annual free cash flow
2020
2021
2022
2023
2024
2025
Cullinan Therapeutics Free Cash Flow (FCF) History (CGEM)
Cullinan Therapeutics reported −$175.8M in free cash flow for fiscal 2025, a decrease of $30.5M from the previous fiscal year.
View full Cullinan Therapeutics company overviewCullinan Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$175.8M | −$30.5M | — | — |
| 2024 | 2024-12-31 | −$145.3M | −$10.8M | — | — |
| 2023 | 2023-12-31 | −$134.5M | −$6.7M | — | — |
| 2022 | 2022-12-31 | −$127.8M | −$84.4M | — | — |
| 2021 | 2021-12-31 | −$43.4M | −$13.7M | — | −229.28% |
| 2020 | 2020-12-31 | −$29.8M | — | — | — |
Cullinan Therapeutics quarterly free cash flow
Q1.20
Q2.20
Q3.20
Q4.20
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | −$36.6M | −$18.5M | — | — |
| Q3 2024 | 2024-09-30 | −$34.1M | $2,000 | — | — |
| Q2 2024 | 2024-06-30 | −$36.3M | −$5.2M | — | — |
| Q1 2024 | 2024-03-31 | −$38.2M | $12.9M | — | — |
| Q4 2023 | 2023-12-31 | −$18.1M | $7.7M | — | — |
| Q3 2023 | 2023-09-30 | −$34.1M | $20.5M | — | — |
| Q2 2023 | 2023-06-30 | −$31.1M | −$5.6M | — | — |
| Q1 2023 | 2023-03-31 | −$51.2M | −$29.2M | — | — |
| Q4 2022 | 2022-12-31 | −$25.9M | −$16.4M | — | — |
| Q3 2022 | 2022-09-30 | −$54.6M | −$45.5M | — | — |
| Q2 2022 | 2022-06-30 | −$25.4M | −$19.2M | — | — |
| Q1 2022 | 2022-03-31 | −$21.9M | −$16.9M | — | — |
| Q4 2020 | 2020-12-31 | −$9.4M | — | — | — |
| Q3 2020 | 2020-09-30 | −$9.1M | — | — | — |
| Q2 2020 | 2020-06-30 | −$6.3M | — | — | — |
| Q1 2020 | 2020-03-31 | −$5.0M | — | — | — |
Cullinan Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$29.8M to −$175.8M, a net decrease of $146.0M. Cullinan Therapeutics's latest reported quarter, Q4 2024, generated −$36.6M in free cash flow, a decrease of $18.5M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Cullinan Therapeutics filings at SEC.gov ↗